

SPECIALTY QUANTITY LIMIT PROGRAM

FASENRA (benralizumab)

I. PROGRAM DESCRIPTION

The standard limit is designed to allow a quantity sufficient for the most common uses of the medication. If the member's plan allows a quantity limit exception review for the requested medication, coverage of an additional quantity may be provided up to the exception limit with prior authorization. The recommended dosing parameters for the treatment of severe eosinophilic asthma fall within the standard limits. Coverage of an additional quantity may be reviewed on a case-by-case basis upon request.

II. COVERED QUANTITIES

Medication	Standard Limit	Exception Limit*	FDA-recommended dosing
Fasenra 30 mg/mL single-dose prefilled syringe/autoinjector	1 syringe per 56 days	3 syringes per 84 days	Initial: 30 mg every 4 weeks for the first 3 doses Maintenance: 30 mg every 8 weeks

*Coverage up to the exception limits may be provided with prior authorization via the Specialty Post Limit Quantity Exception Criteria for approval.

III. REFERENCES

1. Fasenra [package insert]. Wilmington, DE: AstraZeneca; October 2019.